Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 15,800 | $39.41 | $622,678.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,657,588 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $38.90 to $39.88. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,700 | $38.29 | $103,383.00 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,673,388 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $37.85 to $38.84. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 20, 2018 Filed Nov 21, 2018 23:23 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-059818 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,676,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,466 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $44.61 | $40,951.98 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 91,122 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $44.11 to $44.91. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,100 | $45.18 | $49,698.00 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,665,769 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $45.03 to $45.52. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 17,800 | $44.56 | $793,168.00 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,666,869 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $44.03 to $45.015. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 02, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,785 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $44.08 | $40,465.44 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 92,040 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $43.77 to $44.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,500 | $44.42 | $199,890.00 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,674,350 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $44.27 to $44.60. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 14,400 | $43.92 | $632,448.00 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,678,850 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $43.25 to $44.24. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 22:40 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-057017 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,693,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · derivative · entry 17 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,104 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Fully vested. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 300 | $54.69 | $16,407.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 92,958 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F11 · price: The shares were sold at prices ranging from $54.15 to $55.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 618 | $53.20 | $32,877.60 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 93,258 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F10 · price: The shares were sold at prices ranging from $52.90 to $53.75. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,800 | $55.57 | $100,026.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,682,931 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $55.31 to $55.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 4,700 | $54.78 | $257,466.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684,731 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $54.31 to $55.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,300 | $53.74 | $338,562.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,689,431 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $53.31 to $54.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,100 | $52.96 | $323,056.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,695,731 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $52.305 to $53.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,701,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · derivative · entry 16 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,423 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F13 · derivative.exercise_date: Fully vested. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 200 | $55.29 | $11,058.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 93,876 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $55.26 to $55.31. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 718 | $54.36 | $39,030.48 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 94,076 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $53.90 to $54.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 400 | $55.90 | $22,360.00 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,691,512 F1 · kind: Shares sold pursuant to a 10b5-1 plan. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,364 | $55.13 | $295,717.32 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,691,912 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $54.765 to $55.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 13,136 | $54.23 | $712,365.28 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,697,276 F1 · kind: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $53.73 to $54.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2018 Filed Oct 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-055803 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,710,412 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,319 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,742 Underlying: Common Stock · 10,319 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 611 | $59.89 | $36,592.79 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 94,794 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $59.73 to $60.19. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 307 | $58.68 | $18,014.76 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 95,405 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $58.62 to $58.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10,707 | $59.94 | $641,777.58 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700,093 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $59.33 to $60.29. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,193 | $58.82 | $481,912.26 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,710,800 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $58.33 to $59.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,319 | $3.60 | $37,148.40 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,718,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,061 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 200 | $59.37 | $11,874.00 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 95,712 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $59.23 to $59.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 718 | $58.79 | $42,211.22 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 95,912 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $58.22 to $59.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9,902 | $59.16 | $585,802.32 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708,674 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $58.96 to $59.61. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,998 | $58.47 | $526,113.06 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,718,576 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $57.955 to $58.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 22:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-054296 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,727,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,381 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 909 | $58.88 | $53,521.92 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 96,630 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $58.70 to $59.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 9 | $57.64 | $518.76 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 97,539 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $57.45 to $57.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 17,609 | $58.84 | $1,036,113.56 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,717,254 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $58.20 to $59.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,291 | $57.36 | $74,051.76 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,734,863 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $56.85 to $57.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,736,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · derivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,701 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Fully vested. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 208 | $57.48 | $11,955.84 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 97,548 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $57.10 to $57.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 710 | $56.71 | $40,264.10 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 97,756 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $56.20 to $56.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2018 Filed Sep 21, 2018 22:15 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,492 | $57.50 | $430,790.00 |
DisclosureSEC source: 0001209191-18-051973 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,725,834 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $57.05 to $57.825. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.